TNSN04047A1 - Compositions a delitement intra-oral, acceptables du point de vue organoleptique. - Google Patents
Compositions a delitement intra-oral, acceptables du point de vue organoleptique.Info
- Publication number
- TNSN04047A1 TNSN04047A1 TNP2004000047A TNSN04047A TNSN04047A1 TN SN04047 A1 TNSN04047 A1 TN SN04047A1 TN P2004000047 A TNP2004000047 A TN P2004000047A TN SN04047 A TNSN04047 A TN SN04047A TN SN04047 A1 TNSN04047 A1 TN SN04047A1
- Authority
- TN
- Tunisia
- Prior art keywords
- oral
- compositions
- deliting
- intra
- organoleptically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
DES COMPRIMES A DELITEMENT ORAL; FONDANT RAPIDEMENT; ET DES PROCEDES POUR LA PREPARATION DE CES FORMES POSOLOGIQUES SONT PROPOSES. LES COMPOSITIONS SONT UTILES DANS LE TRAITEMENT OU LA PROPHYLAXIE D'UNE LARGE GAMME DE TROUBLES ET D'AFFECTIONS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32535601P | 2001-09-26 | 2001-09-26 | |
PCT/US2002/030048 WO2003026697A2 (fr) | 2001-09-26 | 2002-09-23 | Compositions a desintegration orale, acceptables sur le plan organoleptique |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN04047A1 true TNSN04047A1 (fr) | 2006-06-01 |
Family
ID=23267542
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2004000045A TNSN04045A1 (fr) | 2001-09-26 | 2004-03-23 | Compositions de valdecoxib a delitement intra-oral |
TNP2004000047A TNSN04047A1 (fr) | 2001-09-26 | 2004-03-24 | Compositions a delitement intra-oral, acceptables du point de vue organoleptique. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2004000045A TNSN04045A1 (fr) | 2001-09-26 | 2004-03-23 | Compositions de valdecoxib a delitement intra-oral |
Country Status (25)
Country | Link |
---|---|
US (1) | US20030181501A1 (fr) |
EP (2) | EP1429736A2 (fr) |
JP (2) | JP2005512964A (fr) |
KR (2) | KR20040044990A (fr) |
CN (2) | CN1703203A (fr) |
AP (2) | AP2004002999A0 (fr) |
AR (1) | AR037239A1 (fr) |
BR (2) | BR0212778A (fr) |
CA (2) | CA2461044A1 (fr) |
CO (2) | CO5570659A2 (fr) |
EA (2) | EA200400357A1 (fr) |
EC (1) | ECSP045029A (fr) |
GE (1) | GEP20063856B (fr) |
HK (1) | HK1079988A1 (fr) |
IL (2) | IL160855A0 (fr) |
IS (2) | IS7177A (fr) |
MA (2) | MA27542A1 (fr) |
MX (2) | MXPA04002798A (fr) |
NO (2) | NO20041258L (fr) |
OA (2) | OA12707A (fr) |
PL (2) | PL369298A1 (fr) |
TN (2) | TNSN04045A1 (fr) |
WO (2) | WO2003026697A2 (fr) |
YU (1) | YU34804A (fr) |
ZA (2) | ZA200401953B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002557A1 (fr) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations |
US20050186271A1 (en) * | 2004-02-24 | 2005-08-25 | Sheskey Paul J. | Process for dispersing a fluid in a mass of solid particles |
KR20070040389A (ko) * | 2004-08-10 | 2007-04-16 | 아지노모토 가부시키가이샤 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
CN101115469A (zh) * | 2004-12-28 | 2008-01-30 | 卫材R&D管理有限公司 | 速崩片及其制造方法 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
TW200732000A (en) * | 2005-12-20 | 2007-09-01 | Eisai R&D Man Co Ltd | Orally disintegrating table comprising fat-soluble drug |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865743B2 (en) * | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
WO2007087188A2 (fr) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Comprimes et granules au gout masque |
US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
WO2007142811A2 (fr) * | 2006-05-19 | 2007-12-13 | Somaxon Pharmaceuticals, Inc. | Formulations de doxépine à faible dose, incluant des formulations buccales, sublinguales et à dissolution rapide, et leurs utilisations pour traiter l'insomnie |
JP2010529071A (ja) * | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 速崩性錠剤製造のための医薬製剤 |
CA2686964A1 (fr) * | 2007-06-06 | 2008-12-11 | Basf Se | Preparation pharmaceutique pour produire des comprimes a delitement rapide |
CN101686931B (zh) * | 2007-06-06 | 2013-06-19 | 巴斯夫欧洲公司 | 用于制备可咀嚼片剂和锭剂的药物配制剂 |
WO2008148733A2 (fr) * | 2007-06-06 | 2008-12-11 | Basf Se | Préparation pharmaceutique pour produire des comprimés à délitement rapide |
KR101606944B1 (ko) * | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
EP2268268A2 (fr) * | 2008-03-24 | 2011-01-05 | Wockhardt Research Centre | Compositions orodispersibles de rhéine ou de diacéréine |
US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
KR101704156B1 (ko) * | 2008-11-25 | 2017-02-07 | 미쓰비시 타나베 파마 코퍼레이션 | 구강 내 속붕괴성정을 제조하기 위한 혼합물 |
WO2010144865A2 (fr) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Procédés de traitement de troubles gastro-intestinaux |
US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
CA2178686A1 (fr) * | 1995-06-13 | 1996-12-14 | Leslie G. Humber | Formulations orales de s(+)-etodolac |
AU6964396A (en) * | 1995-10-20 | 1997-05-07 | Pharmacia & Upjohn Company | Blister package |
CN1140267C (zh) * | 1996-05-17 | 2004-03-03 | 麦克公司 | 治疗环加氧酶-2介导的疾病的每天一次的组合物 |
EP0863134A1 (fr) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2 |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
DK1309315T3 (da) * | 2000-08-18 | 2006-10-09 | Pharmacia Corp | Hurtigt disintegrerende oral valdecoxib-formulering |
CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
-
2002
- 2002-09-23 KR KR10-2004-7004373A patent/KR20040044990A/ko not_active Application Discontinuation
- 2002-09-23 JP JP2003530260A patent/JP2005512964A/ja not_active Withdrawn
- 2002-09-23 YU YU34804A patent/YU34804A/sh unknown
- 2002-09-23 JP JP2003530331A patent/JP2005506987A/ja not_active Withdrawn
- 2002-09-23 EP EP02773522A patent/EP1429736A2/fr not_active Withdrawn
- 2002-09-23 GE GE5525A patent/GEP20063856B/en unknown
- 2002-09-23 CN CNA028189078A patent/CN1703203A/zh active Pending
- 2002-09-23 EA EA200400357A patent/EA200400357A1/ru unknown
- 2002-09-23 BR BR0212778-4A patent/BR0212778A/pt not_active IP Right Cessation
- 2002-09-23 BR BR0212861-6A patent/BR0212861A/pt not_active IP Right Cessation
- 2002-09-23 IL IL16085502A patent/IL160855A0/xx unknown
- 2002-09-23 MX MXPA04002798A patent/MXPA04002798A/es unknown
- 2002-09-23 KR KR10-2004-7004334A patent/KR20040058189A/ko not_active Application Discontinuation
- 2002-09-23 US US10/252,222 patent/US20030181501A1/en not_active Abandoned
- 2002-09-23 MX MXPA04002652A patent/MXPA04002652A/es unknown
- 2002-09-23 EP EP02775948A patent/EP1490035A1/fr not_active Withdrawn
- 2002-09-23 OA OA1200400083A patent/OA12707A/en unknown
- 2002-09-23 OA OA1200400082A patent/OA13060A/en unknown
- 2002-09-23 CN CNA028211413A patent/CN1633281A/zh active Pending
- 2002-09-23 AP APAP/P/2004/002999A patent/AP2004002999A0/en unknown
- 2002-09-23 EA EA200400352A patent/EA200400352A1/ru unknown
- 2002-09-23 IL IL16084802A patent/IL160848A0/xx unknown
- 2002-09-23 CA CA002461044A patent/CA2461044A1/fr not_active Abandoned
- 2002-09-23 PL PL02369298A patent/PL369298A1/xx not_active Application Discontinuation
- 2002-09-23 AP APAP/P/2004/002998A patent/AP2004002998A0/en unknown
- 2002-09-23 WO PCT/US2002/030048 patent/WO2003026697A2/fr active Application Filing
- 2002-09-23 PL PL02369297A patent/PL369297A1/xx not_active Application Discontinuation
- 2002-09-23 WO PCT/US2002/030161 patent/WO2003026623A1/fr active Application Filing
- 2002-09-23 CA CA002461630A patent/CA2461630A1/fr not_active Abandoned
- 2002-09-26 AR ARP020103627A patent/AR037239A1/es unknown
-
2004
- 2004-03-10 ZA ZA200401953A patent/ZA200401953B/en unknown
- 2004-03-11 IS IS7177A patent/IS7177A/is unknown
- 2004-03-11 IS IS7178A patent/IS7178A/is unknown
- 2004-03-23 TN TNP2004000045A patent/TNSN04045A1/fr unknown
- 2004-03-23 EC EC2004005029A patent/ECSP045029A/es unknown
- 2004-03-24 TN TNP2004000047A patent/TNSN04047A1/fr unknown
- 2004-03-24 MA MA27587A patent/MA27542A1/fr unknown
- 2004-03-24 MA MA27586A patent/MA27682A1/fr unknown
- 2004-03-25 NO NO20041258A patent/NO20041258L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402364A patent/ZA200402364B/xx unknown
- 2004-03-26 CO CO04028410A patent/CO5570659A2/es not_active Application Discontinuation
- 2004-03-26 CO CO04028409A patent/CO5570684A2/es not_active Application Discontinuation
- 2004-04-15 NO NO20041532A patent/NO20041532L/no not_active Application Discontinuation
-
2006
- 2006-01-04 HK HK06100055.6A patent/HK1079988A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN04047A1 (fr) | Compositions a delitement intra-oral, acceptables du point de vue organoleptique. | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
PL372809A1 (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
IT1282353B1 (it) | Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione | |
MA27132A1 (fr) | Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues | |
TR200002207T1 (tr) | Slekoksib bileşikleri. | |
YU92501A (sh) | Levodop/karbidop/entakapon farmaceutski preparat | |
MA26700A1 (fr) | FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. | |
WO2004071431A3 (fr) | Composition et methode de traitement de troubles neurodegeneratifs | |
WO2007038112A3 (fr) | Composition pharmaceutique conçue pour ameliorer la fonction cognitive | |
ATE402176T1 (de) | Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten | |
BG105302A (en) | Means for improving cognition | |
HUP0302333A2 (hu) | Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
HUP0402178A2 (hu) | 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
WO2002055062A3 (fr) | Comprime pharmaceutique comprenant du mesylate de paroxetine | |
TNSN04056A1 (fr) | Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation | |
MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
HUP0301847A2 (hu) | Adatanszerin alkalmazása neurodegeneratív állapotok megelżzésére és kezelésére alkalmas gyógyszerkészítmények elżállítására | |
DE60126504D1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa | |
IL176217A0 (en) | Pharmaceutical compositions comprising copolymer 1 for treatment of psychiatric disorders | |
TW200514565A (en) | A pharmaceutical composition for use in the prevention and/or treatment of the oral cavity diseases caused by microorganisms |